This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Allogeneic Cell-based Therapy Development
Allogeneic cell-based therapy differs from the rejection of traditional therapies by using specific cells. These cell types have the ability to evade or suppress the immune system, allowing them to be used as allogeneic transplants without the need for concomitant immunosuppression. Allogeneic therapy utilizes cells from healthy animals to create customized treatments, thereby accelerating the development process and reducing manufacturing costs. BioVenic provides veterinary allogeneic cell therapy research services to researchers worldwide to overcome the challenges associated with autologous cell therapy. We are committed to establishing advanced and standardized allogeneic cell therapy study procedures, while also offering individualized customization for various cell types and treatment needs. Our goal is to streamline the preclinical laboratory phase of therapy development and provide expertise in animal cell-based technologies, custom stem cell manufacturing and immune cell gene modification.
To learn more about our custom animal cell solutions, please visit:
Fig.1 Veterinary Cell Therapy Development.
Veterinary allogeneic cell therapy has extensive research and application potential in the field of cell and gene therapy. Our expert animal cell-focused R&D team will serve as your reliable ally to help you achieve large-scale in vitro culture of target cells and establish a robust, effective, and scalable standardized process to meet downstream requirements. We have expertise in developing, culturing, and modifying a variety of animal cells, including mesenchymal stem cells, hematopoietic stem cells, induced pluripotent stem cells, immune cells, and more.
Allogeneic MSC Therapy Development
BioVenic has supported researchers worldwide in the development and production of animal MSCs. We have extensive project experience and expertise in optimizing animal MSC culture conditions to ensure consistent cell quality. In addition, BioVenic offers innovative three-dimensional cell culture technical support. Animal MSCs have mechanisms to evade the immune system, which helps to reduce the challenge of immune rejection in cell therapy. BioVenic's Veterinary Allogeneic MSC Therapy Development provides process development and other cell-related technical services that are beneficial for the development of treatment of autoimmune diseases, tissue damage, and inflammatory diseases in companion animals.
Allogeneic HSC Therapy Development
BioVenic is focused on allogeneic stem cell therapy for companion animals and has pioneered the use of hematopoietic stem cells (HSCs) to treat challenging and complex blood-related diseases. Animal HSCs are a valuable cell resource for cell therapy and regenerative medicine. We help our clients overcome the challenges and limitations associated with the isolation, culture and expansion of HSCs in their application. Our team of dedicated experts is experienced in the development and manufacture of HSCs and is continuously optimizing HSC culture conditions to ensure consistent cell quality and scientific process development.
Allogeneic iPSC Therapy Development
BioVenic supports researchers developing innovative allogeneic induced pluripotent stem cell therapies based on its in-depth understanding and skilled preparation of animal induced pluripotent stem cells. Our technical team has a complete understanding of the fundamental aspects of iPSC-specific properties, reprogramming, and culture systems. We can design culture systems that meet the needs of our clients' personalized therapy development, ensure consistent cell quality, and optimize robust differentiation programs. We are committed to developing animal iPSCs into an important source for future allogeneic cell therapies by capitalizing on their unlimited expansion and pluripotency. At the same time, our proprietary large animal cell gene editing services enable the seamless integration of multiple gene editing techniques using iPSCs..
Allogeneic CAR-T Therapy Development
BioVenic offers specialized services in process development, cell engineering, cell culture, and cell expansion for allogeneic CAR-T therapy research in veterinary medicine. With extensive project experience and standardized process flow, we excel in the development and preparation of animal immune cells. Combined with a diverse team of scientists, we select appropriate technologies for our client's scientific research projects to meet the large-scale expansion requirements of allogeneic programs. We utilize scalable models to actively advance preclinical research and development. At the same time, we maintain batch-to-batch consistency of immune cells throughout the program development phase to ensure therapeutic efficacy and reproducibility of experimental data.
Application Prospects of Allogeneic Cell Therapy for Veterinary Use
| Field | Applications |
| Hematological Diseases | Allogeneic hematopoietic stem cell transplantation is expected to treat blood-related tumors and genetic diseases in companion animals. The new functional cells resulting from the differentiation of hematopoietic stem cells work to replace dysfunctional cells in treating disease. In addition, the recurrence rate is lower compared to traditional therapies. |
| Organ Transplantation | In the field of animal organ transplantation, autologous therapy is insufficient to meet the demand for organs. Allogeneic cell therapy involves the transplantation of normal functioning organs from healthy individuals of the same species into diseased individuals. However, the ongoing challenge is the various complications resulting from long-term immunosuppression. Scientists are continuously searching for efficient methods to enhance the immune response by balancing the regulatory system and the allogeneic response system. |
| Regenerative Medicine | Compared to autologous stem cell therapy, allogeneic adult stem cells offer significant advantages in the field of regenerative medicine. The source of allogeneic cells used for regeneration is more stable and consistent, and they can be cultured and stored in large quantities. In addition, they can be modified to evade the recipient's immune system, overcoming the challenges of allogeneic treatment. For example, promising results were reported with allogeneic MSC therapy for tendon and ligament disorders in horses. |
Why Choose Us?
Integrated Animal Cell Research Services
BioVenic offers comprehensive technical services related to animal stem cells, including isolation, culture, differentiation, transformation and reprogramming.
Standardized Allogeneic Therapy Development
BioVenic has assembled a dedicated team of innovative veterinary allogeneic cell therapy experts to ensure a seamless and efficient process for cell product development, research design and implementation
Comprehensive Veterinary Cell Therapy Development Support
BioVenic specializes in customizing scientific research plans and creating programs for various types of veterinary cell therapy for clients. Our services go beyond autologous cell therapy to provide comprehensive support.
BioVenic has been focused on the rapidly evolving field of veterinary cell therapy for many years. We offer one-stop solutions to researchers worldwide developing allogeneic cell therapy for veterinary use. We combine professional technical knowledge to leverage the benefits of allogeneic solutions and ensure cell source stability and quality. Our extensive project experience and advanced technology system in the field of animal cells guarantee the standardization and scientific rigor of each basic research and treatment research and development operation. If you are interested in veterinary cell therapy and considering developing an allogeneic cell therapy research project, please do not hesitate to contact us for further discussion.